SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (8283)11/15/1999 8:35:00 AM
From: P.M.Freedman  Respond to of 9523
 
WLA is using this to get more $$$ from PFE.
This could be a do-or-die battle for PFE.
nytimes.com



To: James Baker who wrote (8283)11/15/1999 11:34:00 PM
From: P.M.Freedman  Read Replies (1) | Respond to of 9523
 
Pfizer feels deep pain at the relationship with WLA. It is a big lesson for Pfizer. It isn't a good idea that a company relies on selling the products from other companies. I am waiting to hear Pfizer will outline the future of their own new drugs in the R&D meeting tomorrow. $29 may be the bottom line for Pfizer if the lipitor deal gone. However, PFE may get some cashes from the broken deal.
cnnfn.com



To: James Baker who wrote (8283)11/16/1999 7:48:00 PM
From: john dodson  Read Replies (1) | Respond to of 9523
 
WLA has a huge incentive to keep the lipitor deal with PFE going. I certainly hope that they wouldn't shoot themselves in the foot just to hurt PFE. It certainly seems like they would, though, dudn't it?

-A WLA shareholder


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News